| Literature DB >> 35565695 |
Małgorzata Szczuko1, Anhelli Syrenicz2, Katarzyna Szymkowiak1, Aleksandra Przybylska3, Urszula Szczuko1, Jakub Pobłocki2, Danuta Kulpa4.
Abstract
The popularization of the gluten-free diet brings with it a fashion for its use, which can harm the treatment of Hashimoto's disease. The few studies in this regard do not confirm positive changes resulting from a gluten-free diet. At the same time, the presence of other comorbid autoimmune diseases in this group of patients is increasing. This may have important implications for the interpretation of test results and the need for a gluten-free diet in some patients. In this review, the PubMed database was searched for links between a gluten-free diet, Hashimoto's disease, and autoimmune diseases. When analyzing the available literature, we found no basis for introducing a gluten-free diet for the standard management of Hashimoto patients. The recommended diet is instead an anti-inflammatory diet that levels the supply (to compensate for deficiencies) of vitamin D, iodine, and selenium, which are found in plant products rich in polyphenols, antioxidants, and omega-3 fatty acids, as illustrated in this article.Entities:
Keywords: Hashimoto’s disease; anti-TG; anti-TPO; gluten; gluten-free diet
Mesh:
Substances:
Year: 2022 PMID: 35565695 PMCID: PMC9101474 DOI: 10.3390/nu14091727
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
The studies.
| Author, Year | Number of Patients | Duration of the GFD Diet | Age and Gender | Exclusion | Inclusion | Effect | Comment |
|---|---|---|---|---|---|---|---|
| Riseh 2017 | GFD was notapplied | 20–50 years | GFD before the intervention | – | in HD higher levels of anti-tissue transglutaminase and anti-gliadin IgA antibodies were observed | these studies confirmed the increased risk of CD in patients with Hashimoto’s disease and the frequent occurrence of its asymptomatic form in this group of patients | |
| Krysiak 2019 | 6 months | 20–45 years | GFD before the intervention | Euthyroid (0.4–4.5 mU/L) | no change TSH and fT3 and fT4 | because no small intestinal biopsy was performed, it is possible that patients might have had subclinical (asymptomatic) coeliac disease | |
| Ventura 2020 | 6, 12, 24 months | age at diagnosis 10.1 years | – | biopsy-confirmed CD | ↧ anty-TPO | GFD started early may prevent the other autoimmune diseases frequently associated with CD | |
| Kus 2016 | survey research | 18–60 years | – | 75% respondents with HD were treated with levothyroxine | the respondents stated no symptoms of the digestive system after GFD | taking measurements in different places by the patient makes it impossible to compare the results accurately and is unreliable | |
| Konieczny 2019 | survey research | 18–60 years | – | – | respondents found a reduction in the incidence of digestive problems | biochemical studies have not been performed | |
| Pobłocki 2021 | 3, 6, 12 months | 18–55 years | GFD | diagnosed cAITD | level of TSH, fT3, fT4, anti-TPO and anti-TG-no differences were found after 3 and 6 months | the authors ruled out the influence of the gluten-free diet on thyroid parameters in people with Hashimoto’s without CD |
GFD, gluten-free diet; HD, Hashimoto’s disease; CG, control group; IgA, Immunoglobulin A; CD, celiac disease; TSH, thyroid-stimulating hormone; TRAb, Autoantibodies against TSH receptor; TPO, thyroid peroxidase; fT3, free triiodothyronine; fT4, free tetraiodothyronine; TG, thyroglobulin; cAITD, chronic autoimmune thyroiditis; ↧, decrease; ↥, increase.
Figure 1Hashimoto’s warrior alphabet. TSH—thyroid-stimulating hormone; FT3—free triiodothyronine; FT4—free tetraiodothyronine; anti-TSHR-Ab—thyrotropin antibodies; anti-TPO-Ab—antibodies to thyroid peroxidase; anti-TG-Ab—thyroglobulin antibodies; HLA DQ2, DQ8—human leukocyte antigen class II subregion: DQ2, DQ8; anti-tGT—anti-transglutaminase antibodies; anti-DGT—anti deamidated gliadin peptide antibodies; anti-AGA—anti-gliadin antibodies; anti-EMA—endomysial antibodies; anti-GAD—antibodies glutamic acid decarboxylase; ICA—pancreatic islet antibodies; IAA—insulin antibodies; IA-2—antibodies to tyrosine phosphatase; GI—glycemic index; anti-CCP—anti-cyclic citrullinated peptides; HLA DR1, DR4, DR10—human leukocyte antigen class II subregion: DR1, DR4, DR10; ACA—anticardiolipin antibody; anti-21hydrox—21-hydroxylase antibodies; SCC—squamous cell carcinoma; anti-17hydrox—17 hydroxylase antibodies; IFA-Ab —intrinsic factor antibodies; PCA—parietal cell antibodies (Ab); ANA—antinuclear antibodies; ASMA—antismooth-muscle antibody; anti-LKM—liver and kidney microsomal antigens; anti-SLA—anti-soluble liver antigen; anti CTLA-4—antibodies for cytotoxic T cell antigen 4; anti PD—programmed death monoclonal antibodies; −, minus; +, plus; * the biopsy is conclusive; ** the insulin dose is difficult to determine (created with BioRender.com, https://app.biorender.com/, accessed on 30 January 2022).